Published in Neurotoxicology on December 21, 2011
Advantages of repeated low dose against single high dose of kainate in C57BL/6J mouse model of status epilepticus: behavioral and electroencephalographic studies. PLoS One (2014) 0.82
Seizure suppression through manipulating splicing of a voltage-gated sodium channel. Brain (2015) 0.81
Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat. Neuroscience (2013) 0.79
Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice. Metab Brain Dis (2016) 0.75
[Convulsive crisis in Tramadol and caffeine abusers: about 8 cases and review of the literature]. Pan Afr Med J (2012) 0.75
The neurobiology of antiepileptic drugs. Nat Rev Neurosci (2004) 3.24
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04
Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. Neuron (2003) 2.31
Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. J Neurol Sci (2012) 1.97
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med (2004) 1.89
Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure-free patients after epilepsy surgery: a review of current clinical experience. Epilepsia (2004) 1.87
Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia (2005) 1.86
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology (2011) 1.53
Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am J Hum Genet (2010) 1.52
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology (2008) 1.48
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy. Epilepsia (2006) 1.41
Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp Neurol (2007) 1.40
The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis (2006) 1.33
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci (2010) 1.29
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology (2006) 1.18
Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther (2003) 1.14
Behavioral and cognitive alterations, spontaneous seizures, and neuropathology developing after a pilocarpine-induced status epilepticus in C57BL/6 mice. Exp Neurol (2009) 1.13
Neurogenesis in the adult rat piriform cortex. Neuroreport (2006) 1.12
Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology (2007) 1.11
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol (2010) 1.11
Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia (2002) 1.11
Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia (2006) 1.10
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Genetically engineered GABA-producing cells demonstrate anticonvulsant effects and long-term transgene expression when transplanted into the central piriform cortex of rats. Exp Neurol (2002) 1.08
High resolution ultrasound in posterior interosseous nerve syndrome. Muscle Nerve (2013) 1.07
Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem (2005) 1.07
Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology (2006) 1.06
Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology (2010) 1.06
Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther (2006) 1.05
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett (2002) 1.05
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci (2011) 1.02
Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res (2008) 1.01
Pilocarpine vs. lithium-pilocarpine for induction of status epilepticus in mice: development of spontaneous seizures, behavioral alterations and neuronal damage. Eur J Pharmacol (2009) 1.00
Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia (2012) 0.99
The intrahippocampal kainate model of temporal lobe epilepsy revisited: epileptogenesis, behavioral and cognitive alterations, pharmacological response, and hippoccampal damage in epileptic rats. Epilepsy Res (2012) 0.97
Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia (2006) 0.96
Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab (2009) 0.96
Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia (2012) 0.95
Behavioral alterations in a mouse model of temporal lobe epilepsy induced by intrahippocampal injection of kainate. Exp Neurol (2008) 0.95
(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. Nucl Med Biol (2013) 0.93
Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol (2010) 0.93
A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab (2012) 0.91
The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci (2004) 0.91
Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res (2004) 0.91
Issues related to development of antiepileptogenic therapies. Epilepsia (2013) 0.91
Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurotherapeutics (2014) 0.91
Drug resistance in epilepsy: why is a simple explanation not enough? Epilepsia (2007) 0.90
Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis (2008) 0.89
Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats. Neuropharmacology (2010) 0.89
Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res (2004) 0.88
Effect of aging on neurogenesis in the canine brain. Aging Cell (2008) 0.88
Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res (2002) 0.88
The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs (2014) 0.88
Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. Epilepsy Res (2003) 0.87
Marked strain and substrain differences in induction of status epilepticus and subsequent development of neurodegeneration, epilepsy, and behavioral alterations in rats. [corrected]. Epilepsy Res (2011) 0.87
Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia (2002) 0.87
Antiepileptic drug-resistant rats differ from drug-responsive rats in hippocampal neurodegeneration and GABA(A) receptor ligand binding in a model of temporal lobe epilepsy. Neurobiol Dis (2005) 0.87
Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus. Epilepsia (2004) 0.86
Resistance to phenobarbital extends to phenytoin in a rat model of temporal lobe epilepsy. Epilepsia (2007) 0.86
Animal models of limbic epilepsies: what can they tell us? Brain Pathol (2002) 0.86
Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia (2002) 0.86
New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr (2009) 0.86
Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metab Dispos (2013) 0.86
Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia (2008) 0.86
A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. Ann Neurol (2014) 0.85
Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem (2011) 0.85
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging (2011) 0.84
Significant differences in the effects of magnetic field exposure on 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in two substrains of Sprague-Dawley rats. Cancer Res (2004) 0.84
Subregional changes in discharge rate, pattern, and drug sensitivity of putative GABAergic nigral neurons in the kindling model of epilepsy. Eur J Neurosci (2004) 0.84
Targeting post-infarct inflammation by PET imaging: comparison of (68)Ga-citrate and (68)Ga-DOTATATE with (18)F-FDG in a mouse model. Eur J Nucl Med Mol Imaging (2014) 0.84
Epilepsy after head injury in dogs: a natural model of posttraumatic epilepsy. Epilepsia (2013) 0.84
Epilepsy: perampanel-new promise for refractory epilepsy? Nat Rev Neurol (2012) 0.84
Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy. Eur J Neurosci (2013) 0.83
Auditory and vestibular defects and behavioral alterations after neonatal administration of streptomycin to Lewis rats: Similarities and differences to the circling (ci2/ci2) Lewis rat mutant. Brain Res (2007) 0.83
Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia (2007) 0.83
Auditory startle reaction is disinhibited in idiopathic restless legs syndrome. Sleep (2007) 0.82
Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol (2002) 0.82
Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res (2006) 0.82
Epileptic seizures and hippocampal damage after cuprizone-induced demyelination in C57BL/6 mice. Exp Neurol (2007) 0.82
Hirayama disease in Austria. Joint Bone Spine (2012) 0.82
Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur J Pharmacol (2009) 0.82
MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharmacogenomics (2009) 0.82
Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases? Epilepsy Res (2008) 0.82
Benefits and risks of intranigral transplantation of GABA-producing cells subsequent to the establishment of kindling-induced seizures. Neurobiol Dis (2008) 0.81
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nucl Med Biol (2010) 0.81
Generation and characterization of pilocarpine-sensitive C57BL/6 mice as a model of temporal lobe epilepsy. Behav Brain Res (2012) 0.81